ReNerve Limited
RNV.AX · Australian Securities Exchange · AUD
0,084AUD
+0,002 (+2,44 %)Stand 11. Nov., 2:40
Kennzahlen
- Eröffnung
- 0,084
- Vortag
- 0,082
- Tagesspanne
- 0,0835 – 0,084
- 52 Wochen
- 0,068 – 0,22
- Volumen
- 1260
- Ø Volumen
- 68.089
- Börsenwert
- 14,57 Mio. AUD
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 0,2
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Gewinn je Aktie · Erwartet |
|---|
| Gewinn je Aktie · Tatsächlich |
| Abweichung |
| Umsatz · Tatsächlich |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
–
Über das Unternehmen
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; and amniotic tissue product ranges used to aid the healing of wounds under the Empliq brand. In addition, it provides Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand that are in development phase. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
Führung
- Julian John ChickCEO & Executive Director
- David Ian RhodesCSO & Executive Director
- Alex Adamides FRACSChief Medical Officer & Member of Scientific Advisory Board
- David LiljaCFO & Company Secretary
- CEO
- Julian John Chick
- Hauptsitz
- Northcote, VIC, AU
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 25. Nov. 2024
- Website
- renerve.com.au
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.